These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36943430)

  • 1. PD-L1 - targeted magnetic fluorescent hybrid nanoparticles: Illuminating the path of image-guided cancer immunotherapy.
    Li X; Younis MH; Wei W; Cai W
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2240-2243. PubMed ID: 36943430
    [No Abstract]   [Full Text] [Related]  

  • 2. Sensitive and quantitative in vivo analysis of PD-L1 using magnetic particle imaging and imaging-guided immunotherapy.
    Peng Z; Lu C; Shi G; Yin L; Liang X; Song G; Tian J; Du Y
    Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1291-1305. PubMed ID: 36504279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy.
    Yu Y; Li J; Song B; Ma Z; Zhang Y; Sun H; Wei X; Bai Y; Lu X; Zhang P; Zhang X
    Biomaterials; 2022 Jan; 280():121312. PubMed ID: 34896861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
    Moon Y; Shim MK; Choi J; Yang S; Kim J; Yun WS; Cho H; Park JY; Kim Y; Seong JK; Kim K
    Theranostics; 2022; 12(5):1999-2014. PubMed ID: 35265195
    [No Abstract]   [Full Text] [Related]  

  • 5. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
    Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
    J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy.
    Zhu S; Liang B; Zhou Y; Chen Y; Fu J; Qiu L; Lin J
    Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):625-640. PubMed ID: 37878029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Nanotherapeutics for Cancer Immunotherapy by PD-L1-Aptamer-Functionalized and Fexofenadine-Loaded Albumin Nanoparticles.
    Lai X; Yao F; An Y; Li X; Yang XD
    Molecules; 2023 Mar; 28(6):. PubMed ID: 36985529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient PD-L1 gene silence promoted by hyaluronidase for cancer immunotherapy.
    Guan X; Lin L; Chen J; Hu Y; Sun P; Tian H; Maruyama A; Chen X
    J Control Release; 2019 Jan; 293():104-112. PubMed ID: 30476528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CXCR4-targeted nitric oxide nanoparticles deliver PD-L1 siRNA for immunotherapy against glioblastoma.
    Hsieh HT; Huang HC; Chung CW; Chiang CC; Hsia T; Wu HF; Huang RL; Chiang CS; Wang J; Lu TT; Chen Y
    J Control Release; 2022 Dec; 352():920-930. PubMed ID: 36334859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coadministration of iRGD peptide with ROS-sensitive nanoparticles co-delivering siFGL1 and siPD-L1 enhanced tumor immunotherapy.
    Wan WJ; Huang G; Wang Y; Tang Y; Li H; Jia CH; Liu Y; You BG; Zhang XN
    Acta Biomater; 2021 Dec; 136():473-484. PubMed ID: 34571271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxorubicin and PD-L1 siRNA co-delivery with stem cell membrane-coated polydopamine nanoparticles for the targeted chemoimmunotherapy of PCa bone metastases.
    Mu X; Zhang M; Wei A; Yin F; Wang Y; Hu K; Jiang J
    Nanoscale; 2021 May; 13(19):8998-9008. PubMed ID: 33973580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ferrimagnetic Vortex Nanoring-Mediated Mild Magnetic Hyperthermia Imparts Potent Immunological Effect for Treating Cancer Metastasis.
    Liu X; Zheng J; Sun W; Zhao X; Li Y; Gong N; Wang Y; Ma X; Zhang T; Zhao LY; Hou Y; Wu Z; Du Y; Fan H; Tian J; Liang XJ
    ACS Nano; 2019 Aug; 13(8):8811-8825. PubMed ID: 31328922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stearyl polyethylenimine complexed with plasmids as the core of human serum albumin nanoparticles noncovalently bound to CRISPR/Cas9 plasmids or siRNA for disrupting or silencing PD-L1 expression for immunotherapy.
    Cheng WJ; Chen LC; Ho HO; Lin HL; Sheu MT
    Int J Nanomedicine; 2018; 13():7079-7094. PubMed ID: 30464460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.
    Gong C; Yu X; Zhang W; Han L; Wang R; Wang Y; Gao S; Yuan Y
    J Nanobiotechnology; 2021 Feb; 19(1):58. PubMed ID: 33632231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrin α
    Chen H; Zhao L; Fu K; Lin Q; Wen X; Jacobson O; Sun L; Wu H; Zhang X; Guo Z; Lin Q; Chen X
    Theranostics; 2019; 9(25):7948-7960. PubMed ID: 31695808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ICG-labeled PD-L1-antagonistic affibody dimer for tumor imaging and enhancement of tumor photothermal-immunotherapy.
    Jia D; Zhao S; Liu H; Zhan X; Zhou Z; Lv M; Tang X; Guo W; Li H; Sun L; Zhong Y; Tian B; Yuan D; Tang X; Fan Q
    Int J Biol Macromol; 2024 Jun; 269(Pt 2):132058. PubMed ID: 38704065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR-targeted liposomal nanohybrid cerasomes: theranostic function and immune checkpoint inhibition in a mouse model of colorectal cancer.
    Li Y; Du Y; Liang X; Sun T; Xue H; Tian J; Jin Z
    Nanoscale; 2018 Sep; 10(35):16738-16749. PubMed ID: 30156250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Paradigm of Cancer Immunotherapy Based on 2-[18F]FDG and Anti-PD-L1 mAb Combination to Enhance the Antitumor Effect.
    Wen X; Shi C; Zeng X; Zhao L; Yao L; Liu Z; Feng L; Zhang D; Huang J; Li Y; Lin Q; Chen H; Zhuang R; Chen X; Zhang X; Guo Z
    Clin Cancer Res; 2022 Jul; 28(13):2923-2937. PubMed ID: 35320358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioactive fatty acid analog-derived hybrid nanoparticles confer antibody-independent chemo-immunotherapy against carcinoma.
    Tan X; Wang C; Zhou H; Zhang S; Liu X; Yang X; Liu W
    J Nanobiotechnology; 2023 Jun; 21(1):183. PubMed ID: 37291573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Landscape of PD-1/PD-L1 Regulation and Targeted Immunotherapy.
    Ni JM; Ni AP
    Chin Med Sci J; 2018 Sep; 33(3):174-182. PubMed ID: 30266108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.